Amid a mixed market backdrop, penny stocks are drawing renewed attention for their growth potential. We analyze three standout picks, led by financial services firm Siebert Financial, highlighting their financial health and strategic moves in a volatile landscape.
U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
In the shadow of tech giants, two quantum computing specialists, IonQ and D-Wave Quantum, are vying for investor attention with distinct approaches to AI. While both remain speculative bets, a closer look at their technology, finances, and market position reveals one as a potentially less volatile choice for those venturing into this frontier.
IPSASB unveils the world's first dedicated climate reporting standard for governments and public bodies, mandating disclosures from 2028 to illuminate financial risks and opportunities.
Under Armour faces a pivotal moment as a significant insider purchase coincides with a high-stakes legal loss and the exit of its Chief Product Officer, testing investor confidence in the embattled sportswear brand's turnaround strategy.
Five years after its peak, Polkadot (DOT) trades at a staggering 97% discount from its all-time high. Once a top-tier crypto, it has now fallen outside the top 30. We examine whether its steep discount represents a hidden opportunity or a sign of a failed thesis in a market now dominated by Ethereum and Solana.
The refiner's journey from losses to profitability, marked by a rising Return on Capital Employed (ROCE), is drawing investor attention. While its 5.1% ROCE still lags the industry, the positive trajectory suggests strategic reinvestment is paying off.
A sharp $250 billion sell-off across cryptocurrency markets this weekend has been attributed by analysts to a tightening of U.S. dollar liquidity, driven by macro fiscal pressures, rather than a fundamental failure of digital assets.
Nominee Kevin Warsh's desire to aggressively shrink the Federal Reserve's multi-trillion dollar holdings collides with a financial system now structurally dependent on ample liquidity, making rapid contraction a high-risk endeavor, analysts say.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
While passive index funds mirror the broader market, selecting individual winners can dramatically boost returns. Citi Trends (NASDAQ: CTRN) shares have surged 77% over the past year, far exceeding the market's 14% gain, as investors bet on a potential revival despite ongoing profitability challenges.
A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.
A U.S. federal judge has ordered the release of an Ecuadorian asylum-seeking father and his young son, detained in a Minnesota ICE operation, delivering a scathing critique of the administration's immigration enforcement tactics.
A major advisory firm's complete exit from a short-term Treasury ETF is sparking debate on whether institutional investors are moving idle cash into higher-growth opportunities.
While the STOXX Europe 600 edges higher on cautious optimism, a deep dive reveals a pool of fundamentally strong companies trading significantly below their estimated intrinsic value, presenting potential opportunities for discerning investors.
Despite a recent pullback, shareholders in toy and consumer products maker JAKKS Pacific have seen robust long-term gains, with a total shareholder return of 118% over the past five years, fueled by a turnaround to profitability and strategic insider confidence.
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
A Gwinnett County police officer was fatally shot and his partner seriously wounded Sunday while questioning a suspect in a hotel room near Stone Mountain. The gunman, who had an active warrant, invited the officers inside before opening fire.
A strong cash position can signal financial resilience or a lack of growth ambition. We analyze three companies with significant net cash, identifying two with sustainable growth runways and one where the cash pile may mask underlying risks.
